NYSEARCA:AIM - NYSE Arca - US00901B1052 - Common Stock - Currency: USD
We assign a fundamental rating of 1 out of 10 to AIM. AIM was compared to 560 industry peers in the Biotechnology industry. AIM has a bad profitability rating. Also its financial health evaluation is rather negative. AIM is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -176.1% | ||
ROE | -821.74% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 81.05% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.05 | ||
Debt/FCF | N/A | ||
Altman-Z | -49.97 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 0.75 | ||
Quick Ratio | 0.75 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NYSEARCA:AIM (4/4/2025, 8:20:37 PM)
0.0949
-0.02 (-19.37%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 36.11 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 2.36 | ||
P/tB | 18.05 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -176.1% | ||
ROE | -821.74% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 81.05% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.05 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 90% | ||
Cap/Sales | 113.68% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 0.75 | ||
Quick Ratio | 0.75 | ||
Altman-Z | -49.97 |